Abstract
Myocardial Infarction (MI) with Non-obstructive Coronary Arteries (MINOCA) is a syndrome with underlying many causes. MINOCA incidence is estimated to be between 5% and 25% of all MI. The outcome is extremely variable depending on the MINOCA cause. Clinical history, laboratory tests, echocardiography and coronary angiography are the first line diagnostic investigations. Nevertheless, further tests are frequently necessary (e.g. optical coherence tomography, invasive provocative test with acetylcholine or cardiac magnetic resonance) to establish the exact cause, and allowing the adequate risk stratification and management. This is crucial since many patients, particularly those with angiographically normal coronary arteries, are often labelled as ‘noncardiac', therefore missing the chance for appropriate treatment. And this group of patients characterizes substantially worse outcome than previously it was believed. Here, we have reviewed the pathogenesis, diagnosis, prognosis, and management of MINOCA caused by coronary vasospasm or coronary microcirculation dysfunction.
Keywords: Variant angina, coronary spasm, vasospasm, acetylcholine, myocardial infarction with non-obstructive coronary arteries, coronary angiography.
Current Pharmaceutical Design
Title:Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction
Volume: 24 Issue: 4
Author(s): Jacek Bil*, Natalia Pietraszek, Tomasz Pawlowski and Robert J. Gil
Affiliation:
- Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw,Poland
Keywords: Variant angina, coronary spasm, vasospasm, acetylcholine, myocardial infarction with non-obstructive coronary arteries, coronary angiography.
Abstract: Myocardial Infarction (MI) with Non-obstructive Coronary Arteries (MINOCA) is a syndrome with underlying many causes. MINOCA incidence is estimated to be between 5% and 25% of all MI. The outcome is extremely variable depending on the MINOCA cause. Clinical history, laboratory tests, echocardiography and coronary angiography are the first line diagnostic investigations. Nevertheless, further tests are frequently necessary (e.g. optical coherence tomography, invasive provocative test with acetylcholine or cardiac magnetic resonance) to establish the exact cause, and allowing the adequate risk stratification and management. This is crucial since many patients, particularly those with angiographically normal coronary arteries, are often labelled as ‘noncardiac', therefore missing the chance for appropriate treatment. And this group of patients characterizes substantially worse outcome than previously it was believed. Here, we have reviewed the pathogenesis, diagnosis, prognosis, and management of MINOCA caused by coronary vasospasm or coronary microcirculation dysfunction.
Export Options
About this article
Cite this article as:
Bil Jacek*, Pietraszek Natalia , Pawlowski Tomasz and Gil J. Robert , Advances in Mechanisms and Treatment Options of MINOCA Caused by Vasospasm or Microcirculation Dysfunction, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666180108121253
DOI https://dx.doi.org/10.2174/1381612824666180108121253 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
“PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Current Research on Opioid Receptor Function
Current Drug Targets Metabolic Therapy: Lessons from Liver Diseases
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde
Current Cancer Drug Targets The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Cardiovascular Comorbidities of COPD: When Do they Occur and How are they Managed?
Current Respiratory Medicine Reviews Vascular Endothelium: Functioning in Norm, Changes in Atherosclerosis and Current Dietary Approaches to Improve Endothelial Function
Mini-Reviews in Medicinal Chemistry Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology A More Accurate Approach to Molecular Genetics Analysis in Vascular Disease
Cardiovascular & Hematological Disorders-Drug Targets New Approaches for Antithrombotic Antiplatelet Therapies
Current Medicinal Chemistry Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery